AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer

  • A combination of AstraZeneca Plc's AZN Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC).
  • A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.
  • The trial also tested a combination of Imfinzi plus chemotherapy, which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to improve OS significantly.
  • Each combination demonstrated an acceptable safety profile, and no new safety signals were identified.
  • The data will be presented at a forthcoming medical meeting.
  • Price Action: AZN shares are up 0.62% at $53.81 during the market trading session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareGeneralBriefsNon-Small Cell Lung CancerPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!